WEGOVY® 0.25mg is specifically formulated to initiate semaglutide therapy, ensuring safety and tolerability during the first four weeks of treatment.

• Contains 0.25 mg of semaglutide per 0.5 mL dose, administered weekly

• Supplied in a FlexTouch® pre-filled pen for subcutaneous injection

• Designed to be used as a starting dose only in the escalation schedule

• Helps reduce appetite, control food cravings, and regulate blood sugar

• Based on GLP-1 analogue technology, mimicking the body’s natural satiety signals

WEGOVY® 0.25mg is indicated for weight reduction and weight maintenance in adult patients with the following criteria:

• Obesity (BMI ≥30 kg/m²), or

• Overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia

It must be used in conjunction with dietary changes and physical exercise.

Contraindications:

• Hypersensitivity to semaglutide or any component of the formulation

• Personal or family history of medullary thyroid carcinoma (MTC)

• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Pregnancy or breastfeeding

Potential Side Effects:

• Very common: Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue

• Common: Injection site reactions, dizziness, hypoglycemia (when used with other diabetic meds), hair loss, indigestion

• Uncommon to rare: Gallstones, pancreatitis, kidney injury, allergic reactions

WEGOVY® FLEXTOUCH® 0.25mg is delivered in a multi-dose, pre-filled FlexTouch® pen specifically developed for user-friendly self-injection. Each pen contains four doses of semaglutide 0.25 mg.

Packaging:

• 1 FlexTouch® pen pre-filled with semaglutide 1.5 mL solution (0.25 mg per 0.5 mL dose)

• Used with NovoFine® Plus disposable needles (sold separately)

• Each pen delivers 4 weekly doses

Ingredients:

• Active ingredient: Semaglutide 0.25 mg per 0.5 mL

• Excipients: Disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide, water for injection

WEGOVY® 0.25mg is administered via subcutaneous injection once a week, ideally on the same day each week. The dose should be injected into the abdomen, thigh, or upper arm, rotating sites each time to reduce irritation. This dose is not intended for long-term maintenance but rather as part of a gradual escalation.

Usage Instructions:

• Dose: 0.25 mg once weekly for 4 weeks only

• Followed by: 0.5 mg in weeks 5–8, eventually reaching maintenance dose (2.4 mg)

• Administration: Subcutaneous injection using the FlexTouch® pen

• Missed Dose: Administer within 5 days of the scheduled time; otherwise, skip and resume regular schedule

Storage Guidelines:

• Before first use: Refrigerate at 2–8°C

• After opening: Store below 30°C for up to 8 weeks

• Do not freeze or expose to direct sunlight

• Discard pen after 4 doses; do not reuse needles